Skip to main content English



New England BioLabs GmbH

Established in the mid 1970s, New England Biolabs (NEB) is an industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research.

Our ever-expanding catalog also includes products related to (q)PCR, gene editing, synthetic biology, glycobiology, epigenetics & RNA synthesis. Moreover, we advance sample preparation for next generation sequencing, incl. target enrichment and genotyping solutions. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics.

New England Biolabs is a privately held company, headquartered in Ipswich, MA (USA). NEB GmbH is the NEB service hub for Central Europe.



Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Our mission is to develop, manufacture and supply life-enhancing and life-sustaining medicines for the treatment of rare and complex diseases. In our work we are committed to our patients, employees and the environment.


In Austria, Takeda is the largest pharmaceutical employer. Every day, more than 4,500 employees help to ensure that medicines from Austria reach the whole world and that patients in Austria have access to innovative medicines from Takeda. Takeda's Austrian product portfolio helps patients in the fields of oncology, hemophilia and genetic diseases, gastroenterology and immunology, among others.



For more information please visit our homepage.




For over 50 years, Bio-Rad has provided high-quality products and services that advance scientific discovery and improve health care. Our global network of operations allows us to serve research and industry customers
throughout the world. We expanded our product portfolio into cell biology and new PCR techniologies such as Digital droplet PCR. Our investment in R&D and new technologies provides a solid base for future success.




Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

For more information please visit: